Abstract
This article delves into the intersection of generative AI and digital twins within drug discovery, exploring their synergistic potential to revolutionize pharmaceutical research and development. Through various instances and examples, we illuminate how generative AI algorithms, capable of simulating vast chemical spaces and predicting molecular properties, are increasingly integrated with digital twins of biological systems to expedite drug discovery. By harnessing the power of computational models and machine learning, researchers can design novel compounds tailored to specific targets, optimize drug candidates, and simulate their behavior within virtual biological environments. This paradigm shift offers unprecedented opportunities for accelerating drug development, reducing costs, and, ultimately, improving patient outcomes. As we navigate this rapidly evolving landscape, collaboration between interdisciplinary teams and continued innovation will be paramount in realizing the promise of generative AI and digital twins in advancing drug discovery.
Original language | English |
---|---|
Pages (from-to) | 1441-1456 |
Number of pages | 16 |
Journal | BioMedInformatics |
Volume | 4 |
Issue number | 2 |
Early online date | 6 Jun 2024 |
DOIs | |
Publication status | Published - Jun 2024 |
Bibliographical note
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Keywords
- digital twins
- drug development
- generative AI
- prospective analysis
ASJC Scopus subject areas
- Computer Science (miscellaneous)
- Health Informatics
- Health Professions (miscellaneous)
- Medicine (miscellaneous)